{"id":"npo-11","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, NPO-11 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.","oneSentence":"NPO-11 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:30.162Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT03263910","phase":"PHASE3","title":"Study of NPO-11 in Patients Undergoing Gastrointestinal Endoscopy","status":"COMPLETED","sponsor":"Nihon Pharmaceutical Co., Ltd","startDate":"2017-08-21","conditions":"Patients Undergoing Gastrointestinal Endoscopy","enrollment":220},{"nctId":"NCT01411176","phase":"PHASE3","title":"Phase III Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy","status":"COMPLETED","sponsor":"Nihon Pharmaceutical Co., Ltd","startDate":"2011-09","conditions":"Gastric Cancer","enrollment":85},{"nctId":"NCT01411189","phase":"PHASE3","title":"Phase III Open-labeled Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy","status":"COMPLETED","sponsor":"Nihon Pharmaceutical Co., Ltd","startDate":"2011-09","conditions":"Gastric Cancer, Colon Nos Polypectomy Tubular Adenoma, Gastric Adenoma","enrollment":33},{"nctId":"NCT00745459","phase":"PHASE3","title":"Phase III General Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy","status":"COMPLETED","sponsor":"Nihon Pharmaceutical Co., Ltd","startDate":"2008-09","conditions":"Stomach Diseases","enrollment":100},{"nctId":"NCT00740324","phase":"PHASE3","title":"Exploratory Study of Additional Use of Scopolamine Butylbromide, Glucagon or NPO-11 Following Single Dose of NPO-11 in Healthy Adult Men","status":"COMPLETED","sponsor":"Nihon Pharmaceutical Co., Ltd","startDate":"2008-08","conditions":"Healthy","enrollment":30},{"nctId":"NCT00742599","phase":"PHASE3","title":"Phase III Controlled Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy","status":"COMPLETED","sponsor":"Nihon Pharmaceutical Co., Ltd","startDate":"2008-09","conditions":"Patients Undergoing Gastric Endoscopy","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"NPO-11","genericName":"NPO-11","companyName":"Nihon Pharmaceutical Co., Ltd","companyId":"nihon-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NPO-11 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}